<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01186107</url>
  </required_header>
  <id_info>
    <org_study_id>2009-0220</org_study_id>
    <nct_id>NCT01186107</nct_id>
  </id_info>
  <brief_title>Comparison of Zotarolimus-Eluting Stent vs Sirolimus-Eluting Stent for Diabetic Patients</brief_title>
  <acronym>ESSENCE-DM2</acronym>
  <official_title>Randomized Comparison of Zotarolimus-Eluting Stent Versus Sirolimus-Eluting Stent Implantation for De Novo Coronary Artery DisEase in Patients With DIABETES Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seung-Jung Park</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CardioVascular Research Foundation, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CardioVascular Research Foundation, Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish the safety and effectiveness of coronary stenting&#xD;
      with the Zotarolimus-Eluting stent compared to the Sirolimus-Eluting stent in the treatment&#xD;
      of de novo coronary stenosis in patients with diabetic patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, two arms, single blind, randomized multi-center trial of 380 patients enrolled&#xD;
      at 24 centers in Korea. Following angiography, diabetic patients with significant diameter&#xD;
      stenosis &gt;50% by visual estimation have documented myocardial ischemia or symptoms of angina,&#xD;
      and eligible for stenting without any exclusion criteria will be randomized 1:1 to: a)&#xD;
      Endeavor Resolute stent vs. b) Cypher select. All patients will be followed for at least 1&#xD;
      year. Angiographic follow-up at 9-months is routinely recommended.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Angiographic in-segment late loss</measure>
    <time_frame>9-month angiographic follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death (all-cause and cardiac)</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>myocardial infarction</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stent thrombosis</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target-lesion revascularization</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target-vessel revascularization</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">256</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Endeavor Resolute stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>zotarolimus-eluting stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cypher stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sirolimus-eluting stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endeavor Resolute stent</intervention_name>
    <description>zotarolimus-eluting stent</description>
    <arm_group_label>Endeavor Resolute stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cypher stent</intervention_name>
    <description>sirolimus-eluting stent</description>
    <arm_group_label>Cypher stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diabetic patients with angina and documented ischemia&#xD;
&#xD;
          -  Patients who are eligible for intracoronary stenting&#xD;
&#xD;
          -  De novo lesion&#xD;
&#xD;
          -  Percent diameter stenosis ≥50%&#xD;
&#xD;
          -  Reference vessel size ≥ 2.5 mm by visual estimation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of bleeding diathesis or coagulopathy&#xD;
&#xD;
          -  Pregnant state&#xD;
&#xD;
          -  Known hypersensitivity or contra-indication to contrast agent and heparin&#xD;
&#xD;
          -  Limited life-expectancy (less than 1 year)&#xD;
&#xD;
          -  Acute ST elevation myocardial infarction on admission&#xD;
&#xD;
          -  Characteristics of lesion Left main disease In-stent restenosis Graft vessels&#xD;
&#xD;
          -  Hematological disease (Neutropenia &lt;3000/mm3, Thrombocytopenia &lt;100,000/mm3)&#xD;
&#xD;
          -  Hepatic dysfunction, liver enzyme (ALT and AST) elevation ≥ 3 times normal&#xD;
&#xD;
          -  Renal dysfunction, creatinine ≥ 2.0mg/dL&#xD;
&#xD;
          -  Contraindication to aspirin, clopidogrel or cilostazol&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt;30%&#xD;
&#xD;
          -  Patients who are actively participating in another drug or device - investigational&#xD;
             study, which have not completed the primary endpoint follow- up period.&#xD;
&#xD;
          -  Non-cardiac co-morbid conditions are present with life expectancy &lt;1 year or that may&#xD;
             result in protocol non-compliance (per site investigator's medical judgment).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung-Jung Park</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>Anyang</city>
        <state>Gyeong-gi</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soonchunhyang University Bucheon Hospital</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soonchunhyang University Cheonan Hospital</name>
      <address>
        <city>Cheonan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangwon University Hospital</name>
      <address>
        <city>Chuncheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daejeon St Mary's Hospital Catholic University</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GangNeung Asan Hospital</name>
      <address>
        <city>GangNeung</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul Veterans Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>August 19, 2010</study_first_submitted>
  <study_first_submitted_qc>August 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2010</study_first_posted>
  <last_update_submitted>July 28, 2014</last_update_submitted>
  <last_update_submitted_qc>July 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>CardioVascular Research Foundation, Korea</investigator_affiliation>
    <investigator_full_name>Seung-Jung Park</investigator_full_name>
    <investigator_title>M.D., Ph.D.,Professor of Medicine Asan Medical Center, University of Ulsan, College of Medicine</investigator_title>
  </responsible_party>
  <keyword>coronary disease</keyword>
  <keyword>stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

